This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Antibodies Market

Market Insights on Antibodies covering sales outlook, demand forecast & up-to-date key trends

Antibodies Market by Disease Indication (Cardiovascular diseases, CNS disorders, Cancer, Autoimmune Disorders), Product Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)), End User & Region - Forecast to 2021-2031

Antibodies Market Snapshot

Antibodies Market will grow by 21x in upcoming decade, surpassing US$ 601.614 Billion by the end of 2031, finds Future Market Insights (FMI).

North America is anticipated to dominate the Antibodies Market holding around 45.8% of the overall market share in 2021. The growth can be attributed to rising awareness, increasing government funding to find treatment for chronic ailments and presence of leading market players in U.S. and Canada.

FMI also states that, F. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson Services, Inc., Amgen Inc., and Bristol-Myers Squibb Company are leading players operating in the antibodies market. Collectively they will account for 3 out of 4 sales of antibodies across the globe.

Customize this Report

Let us know your requirement to get
100% FREE customization

Antibodies Market - Key Points Covered in Study

  • Antibodies Market estimates and forecast 2021 – 2031
  • Key drivers and restrains impacting Antibodies Market growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competitive Mapping and Benchmarking
  • Brand share and Market Share Analysis
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact On Antibodies Market and How to Navigate
  • Recommendation on Key Winning Strategies

Antibodies Market Outlook In Comparison to 2021 – 2031 Forecast

Antibodies are essential for treating medical conditions like autoimmune diseases, cancer, and various type neurological diseases. Certain type of antibodies called immunoglobulin (IG) is used for the prevention of lower respiratory tract infections and diseases caused by vaccinia virus. Rising cases of viral infection will drive the demand for antibodies.

National Stem Cell Foundation (NSCF) has reported that about 4% of global population is affected by some kind of autoimmune diseases. The most common autoimmune diseases are diabetes, multiple sclerosis, Crohn’s disease and rheumatoid arthritis.

Autoimmune diseases also act as a host for multiple chronic ailments. As the prevalence of autoimmune diseases is on the rise, the demand for antibodies is forecast to increase in upcoming years.

In April 2021, Xencor commenced its Phase I clinical trial of its new engineered Interleukin-2 (IL-2) Fc cytokine and XmAb564 antibody therapeutics designed for developing treatment of patients with autoimmune diseases.

The COVID-19 pandemic boosted the demand for antibodies as patients suffering from COVID-19 were highly susceptible to contracting various other ailments and in some cases triggered the autoimmune diseases in the patient.

Zydus Cadila is planning to launch its own antibody cocktail, ZRC-3308, through trials in India. The antibody cocktails are used in COVID-19 patients who are at risk of progressing to severe disease.

Novel biosimilar antibodies manufacturers are slashing their prices to compete with branded antibodies manufacturers especially in European market. With expiration of patents of renowned products, a boost in demand for biosimilar antibodies can be expected in upcoming years.

Antibodies Market Download Report Brochure

How do Research and Development Activities Impact Antibodies Sales Outlook?

Surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies and biosimilar antibodies are driving the market growth.

In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health’s rapid test contract development and manufacturing services.

In September 2020, Regeneron collaborated with Roche for efficient clinical trials of their monoclonal antibody treatment (REGN-COV2) for COVID-19.

Rising cases of multiple sclerosis and Parkinson’s disease among older population is key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, and novel and effective treatments in middle income countries. This is expected to positively influence the sales of antibodies.

In 2021, Berkeley Lights, a digital cell biology company joined hands with Genovac, an antibody discovery company to readily access the right antibodies in the shortest amount of time with the help of modern technology.

Considering this, the rising application of antibodies in chronic diseases treatment will create scope for market expansion in the near future.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How Is Increasing Production of Bio-similar Antibodies driving Demand?

Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies and they have very few side effects.

In 2020, Johnson and Johnson reported US$ 3.75 Bn achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade generated US$ 659 Mn in 2020.

U.S. Food and Drug Administration (FDA) approved a biosimilar of Remicade called “Avsola” in December 2019, and are now eligible for producing biologics product all over the world.

Increasing demand for biosimilar antibodies in treatment of rheumatoid arthritis along with high patient acceptance rate will boost the market growth.

One of the leaders in prescription medicines, Pfizer received the EU approval for biosimilar antibody therapeutics “Amsparity” for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020.

Elevated new drug approval rates and products in the clinical trials in pharmaceutical companies will drive the market in upcoming years.

Antibodies Market Country-wise Analysis

Why Is U.S Dominating The Global Antibodies Market?

The U.S. is the leading manufacturer of antibodies owing to modern healthcare infrastructural facilities and presence of leading market players in the country. Increasing purchasing power of consumers along with increasing government funding will drive the market growth.

National Health Accounts by Centers for Medicare & Medicaid Services (CMS) in its report states that healthcare spending in U.S. grew by around 4.6% in 2019. Rising cases of cancer and autoimmune diseases in the country will further increase the demand for antibodies.

National Stem Cell Foundation (NSCF) states that, autoimmune diseases are the third most common reason of chronic ailments in U.S. Increasing cases of diabetes and multiple sclerosis in the country will positively influence the demand for antibodies.

In February 2021, U.S. Food and Drug Administration (FDA) issued the authorization for bamlanivimab and etesevimab monoclonal antibodies administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients suffering for SARS-CoV-2 and are succeptible to progressing to severe case. This will accelerate the demand for antibodies in the country for years to come.

What Are The Factors Driving Antibodies Demand In Saudi Arabia?

GCC countries led by Saudi Arabia is emphasizing on early diagnosis and screening of cancer to elevate the survival rate and chance of successful treatment. Increasing screening and diagnosis using biosimilar antibodies therapeutics will bode well with market growth in the region.

Around 1291 new cases of childhood cancer were reported in Saudi Arabia in 2020, as per the report from World Health Organization (WHO). Increasing establishment of biotechnology research and development centers to develop cancer monoclonal antibodies will drive the market growth in upcoming years.

Market Players are working towards developing antibodies which are effective in treating COVID-19. Biotech company SaudiVax and U.S. firm Abound Bio jointly announced a licensing agreement for developing COVID-19 treatment.

The companies discovered a human monoclonal antibodies showcasing high potency in neutralizing activity against SARS-CoV-2. This will create growth opportunities in Saudi Arabia.

How Will Antibodies Market Growth Unfold in China?

World Bank evaluated that the healthcare expenditure in China was accounted for 5.35% of its gross domestic product (GDP) in 2018. Rising geriatric population and associated ailments will drive the market growth in upcoming years.

Development and production of antibodies in China is expected to increase significantly owing to increasing government investment towards drugs development coupled with growing awareness about various medical ailments like rheumatoid arthritis, cancer and infections.

Chine developed its first U.S. Food and Drug Administration (FDA) approved antibody in March 2018.The antibody named “Trogarzo” was useful in treating resistant HIV infections. Similarly more than ten other China made biologics are under clinical trials.

The government also started a “Chinese Antibody Society” with the aim to assist in speedy FDA approval as well as ensure effective marketing of China made antibody-based therapeutics.

These initiatives are expected to reflect positively on the China market, presenting conducive environment for the growth of antibodies sales.

What is Influencing Antibodies Market Growth In India?

Indian antibodies market is anticipated to grow at a rapid pace owing to rising cases of cancer and cardiovascular diseases along with development of healthcare system in the country.

As per the data from Global Cancer Observatory, 1.322 million new cancer cases were registered in India in 2020, while 2.72 million people had cancer for 5 years. Surge in cancer patients will drive the demand for monoclonal antibodies for cancer treatment.

Antibodies are finding its use in developing treatment for ongoing COVID-19 pandemic. World Health Organization has reported that around 29.97 million people were infected with COVID-19 in India as of June 2021. These numbers indicate huge potential for monoclonal antibodies market in India.

In 2021, Roche collaborated with Cipla to provide monoclonal antibody drugs called “REGEN-COV2”. REGEN-COV2 is a cocktail of monoclonal antibodies casirivimab and imdevimab and has received strict medical emergency approval.

Rapid technological advancements, increasing government funding to make the treatment affordable, and increasing consumer spending on healthcare will create opportunities for growth in India.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Antibodies Market Category-wise Insights

Why Are Cancer Antibodies Gaining Popularity?

Rising prevalence of non-Hodgkin lymphoma and other type of cancer has fuelled the demand for cancer antibodies for developing noninvasive and safe treatment options. With focus on cancer research increasing, the antibodies market outlook for the upcoming decade will remain positive.

Which Product Will Register High Demand?

Monoclonal antibodies are predicted to showcase elevated demand throughout the forecast period owing to rising drug approval rates. Besides this, sales in this category will rise in response to the increasing cases of rheumatoid arthritis, psoriasis, and asthma in geriatric population across the globe. The rising demand for effective treatment of aforementioned chronic ailments will remain a chief growth driver in this category.

Who is the Leading End User of Antibodies?

Hospitals are expected to generate highest demand throughout the forecast period. Growing pool of patients and faster accessibility to healthcare will elevate the demand in Hospitals.

Hospitals around the world register a higher footfall of patients as they offer expert care and infrastructure required for administering necessary treatment. Antibodies demand in hospitals multiplied amid COVID-19 outbreak.

Even as governments roll out vaccination drives to contain the pandemic, hospitals will remain dominant end user on account of rising cases of various types of chronic ailments.

Antibodies Market - Competitive Landscape

Future Market Insights (FMI) has found that market players are working towards developing new antibodies to treat cancer and other diseases. They are also researching to create long acting antibody drugs to reduce healthcare cost.

In order to gain a competitive edge in the antibodies market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic merger and acquisition for portfolio expansion is in the cards as well.

On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment “iptacopan”, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that, during 12 weeks of iptacopan monotherapy treatment no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.

In August 2020, Johnson & Johnson entered into final agreement to acquire Momenta Pharmaceuticals Inc. for around US$ 6.5 Bn. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.

The acquisition will allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth through expansion into autoantibody-driven disease.

Antibodies Market – Report Scope

Attribute

Details

Forecast Period

2021 – 2031

Historical Data Available for

2016 – 2026

Market Analysis

US$ Mn for Value & Units for Volume

Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa

Key Segments Covered

By Disease Indication, End user, Product Type, Region

Key Companies Profiled

  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Sanofi SA
  • Eli Lilly and Co.

Report Coverage

Market Overview, Market Background, Market Forecast, Segmental Analysis, Regional Profiling and Competition Analysis

Customization & Pricing

Available upon Request

Key Segments Covered in Antibodies Market Study

By Disease Indication

  • Cardiovascular diseases
  • CNS disorders
  • Cancer
  • Autoimmune Disorders

By Product Type

  • Monoclonal antibodies
  • Polyclonal antibodies
  • Antibody-drug complexes (ADCs) 

By End User

  • Hospitals
  • Long-term Care Facilities
  • Research institutes

By Region

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East and Africa (MEA)

Frequently Asked Questions

Driven by increasing research in monoclonal antibodies in treating autoimmune disease, the antibodies market size is forecast to reach US$ 186.865 Billion in 2021.

Between 2016 and 2020, the antibodies market grew at 9.50% CAGR owing to increasing cases of cancer and diabetes in last 5 years.

The market valuation of antibiotics is forecast to reach US$ 601.607 Billion by the end of 2031.

U.S., Switzerland, and France are leading producers of the antibodies owing to presence of leading market players and dedicated research facilities in these countries.

Demand registered in North America will continue rising, backed by presence of leading market players in the U.S. and Canada, the North America market is predicted to account for 49.2% market share by 2031.

F. Hoffmann-La Roche Ltd., AbbVie Inc., Johnson & Johnson Services Inc., Amgen Inc., and Bristol-Myers Squibb Company are the top five companies operating in the market.

Top five players account for nearly 75% of the antibodies market in 2021.

Antibodies sales will increase at 11.3% CAGR in Europe, backed by rising demand in the U.K., Germany and other countries.

Leading countries driving demand in the antibodies market are U.S., Japan, China, U.K., and Canada.

As of 2021, Japan and China holds around 10.3% and 4.3% share respectively in the global antibodies market.

Table of Content

1. Executive Summary

2. Assumptions and Acronyms

3. Research Methodology

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Market Taxonomy

        4.1.3. Market Product Type Overview

        4.1.4. Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity

    4.3. Regulations

5. Global Market Forecast

    5.1. Market Value (US$ Mn) Forecast

        5.1.1. Y-o-Y Growth Projections

        5.1.2. Absolute $ Opportunity

    5.2. Market Trends

        5.2.1. Market Share, By Region

        5.2.2. Market Share, By Product Type

        5.2.3. Market Share, By End User

        5.2.4. Market Share, By Disease Indication

6. Global Market Analysis, By Product Type

    6.1. Introduction

        6.1.1. Y-o-Y Growth Comparison, By Product Type

        6.1.2. Market Share & Basis Point (BPS) Analysis, By Product Type

    6.2. Market Forecast, By Product Type

        6.2.1. Monoclonal antibodies

            6.2.1.1. Absolute $ Opportunity

            6.2.1.2. Market Value (US$ Mn) Forecast

        6.2.2. Polyclonal antibodies

            6.2.2.1. Absolute $ Opportunity

            6.2.2.2. Market Value (US$ Mn) Forecast

        6.2.3. Antibody-drug complexes (ADCs)

            6.2.3.1. Absolute $ Opportunity

            6.2.3.2. Market Value (US$ Mn) Forecast

        6.2.4. Market Attractiveness Analysis, By Product Type

        6.2.5. Prominent Trends

7. Global Market Analysis, By Disease Indication

    7.1. Introduction

        7.1.1. Y-o-Y Growth Comparison, By Disease Indication

        7.1.2. Market Share & Basis Point (BPS) Analysis, By Disease Indication

    7.2. Market Forecast, By Disease Indication

        7.2.1. Cardiovascular diseases

            7.2.1.1. Absolute $ Opportunity

            7.2.1.2. Market Value (US$ Mn) Forecast

        7.2.2. CNS disorders

            7.2.2.1. Absolute $ Opportunity

            7.2.2.2. Market Value (US$ Mn) Forecast

        7.2.3. Cancer

            7.2.3.1. Absolute $ Opportunity

            7.2.3.2. Market Value (US$ Mn) Forecast

        7.2.4. Autoimmune Disorders

            7.2.4.1. Absolute $ Opportunity

            7.2.4.2. Market Value (US$ Mn) Forecast

        7.2.5. Market Attractiveness Analysis, By Disease Indication

        7.2.6. Prominent Trends

8. Global Market Analysis, By End User 

    8.1. Introduction

        8.1.1. Y-o-Y Growth Comparison, By End User

        8.1.2. Market Share & Basis Point (BPS) Analysis, By End User

    8.2. Market Forecast, By End User

        8.2.1. Hospitals

            8.2.1.1. Absolute $ Opportunity

            8.2.1.2. Market Value (US$ Mn) Forecast

        8.2.2. Long-term Care Facilities

            8.2.2.1. Absolute $ Opportunity

            8.2.2.2. Market Value (US$ Mn) Forecast

        8.2.3. Research institutes

            8.2.3.1. Absolute $ Opportunity

            8.2.3.2. Market Value (US$ Mn) Forecast

        8.2.4. Market Attractiveness Analysis, By End User

        8.2.5. Prominent Trends

9. Global Market Analysis, By Region

    9.1. Introduction

        9.1.1. Y-o-Y Growth Projections, By Region

        9.1.2. Market Share & Basis Point (BPS) Analysis, By Region

    9.2. Market Forecast, By Region

        9.2.1. North America Market Value (US$ Mn) Forecast

        9.2.2. Latin America Market Value (US$ Mn) Forecast

        9.2.3. Western Europe Market Value (US$ Mn) Forecast

        9.2.4. Eastern Europe Market Value (US$ Mn) Forecast

        9.2.5. Asia Pacific Excl. Japan Market Value (US$ Mn) Forecast

        9.2.6. Japan Market Value (US$ Mn) Forecast

        9.2.7. MEA Market Value (US$ Mn) Forecast

    9.3. Regional Attractiveness Analysis

10. North America Market Analysis

    10.1. Introduction

        10.1.1. Y-o-Y Growth Projections, By Country

        10.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    10.2. Key Regulations

    10.3. Key Trends

    10.4. North America Market Forecast

        10.4.1. Market Value (US$ Mn) Forecast, By Country

            10.4.1.1. S. Absolute $ Opportunity

            10.4.1.2. Canada Absolute $ Opportunity

        10.4.2. Market Value (US$ Mn) Forecast, By Product Type

            10.4.2.1. Monoclonal antibodies

            10.4.2.2. Polyclonal antibodies

            10.4.2.3. Antibody-drug complexes (ADCs)

        10.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            10.4.3.1. Cardiovascular diseases

            10.4.3.2. CNS disorders

            10.4.3.3. Cancer

            10.4.3.4. Autoimmune Disorders

        10.4.4. Market Value (US$ Mn) Forecast, By End User

            10.4.4.1. Hospitals

            10.4.4.2. Long-term Care Facilities

            10.4.4.3. Research institutes

        10.4.5. Market Attractiveness Analysis

            10.4.5.1. By Country

            10.4.5.2. By Product Type

            10.4.5.3. By End User

            10.4.5.4. By Disease Indication

        10.4.6. Drivers & Restraints: Impact Analysis

11. Latin America Market Analysis

    11.1. Introduction

        11.1.1. Y-o-Y Growth Projections, By Country

        11.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    11.2. Key Regulations

    11.3. Key Trends

    11.4. Latin America Market Forecast

        11.4.1. Market Value (US$ Mn) Forecast, By Country

            11.4.1.1. Argentina Absolute $ Opportunity

            11.4.1.2. Brazil Absolute $ Opportunity

            11.4.1.3. Mexico Absolute $ Opportunity

            11.4.1.4. Rest of Latin America Absolute $ Opportunity

        11.4.2. Market Value (US$ Mn) Forecast, By Product Type

            11.4.2.1. Monoclonal antibodies

            11.4.2.2. Polyclonal antibodies

            11.4.2.3. Antibody-drug complexes (ADCs)

        11.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            11.4.3.1. Cardiovascular diseases

            11.4.3.2. CNS disorders

            11.4.3.3. Cancer

            11.4.3.4. Autoimmune Disorders

        11.4.4. Market Value (US$ Mn) Forecast, By End User

            11.4.4.1. Hospitals

            11.4.4.2. Long-term Care Facilities

            11.4.4.3. Research institutes

        11.4.5. Market Attractiveness Analysis

            11.4.5.1. By Country

            11.4.5.2. By Product Type

            11.4.5.3. By End User

            11.4.5.4. By Disease Indication

        11.4.6. Drivers & Restraints: Impact Analysis

12. Western Europe Market Analysis

    12.1. Introduction

        12.1.1. Y-o-Y Growth Projections, By Country

        12.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    12.2. Key Regulations

    12.3. Key Trends

    12.4. Western Europe Market Forecast

        12.4.1. Market Value (US$ Mn) Forecast, By Country

            12.4.1.1. K. Absolute $ Opportunity

            12.4.1.2. Germany Absolute $ Opportunity

            12.4.1.3. France Absolute $ Opportunity

            12.4.1.4. Spain Absolute $ Opportunity

            12.4.1.5. Italy Absolute $ Opportunity

            12.4.1.6. Nordic Countries Absolute $ Opportunity

            12.4.1.7. Rest of Western Europe Absolute $ Opportunity

        12.4.2. Market Value (US$ Mn) Forecast, By Product Type

            12.4.2.1. Monoclonal antibodies

            12.4.2.2. Polyclonal antibodies

            12.4.2.3. Antibody-drug complexes (ADCs)

        12.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            12.4.3.1. Cardiovascular diseases

            12.4.3.2. CNS disorders

            12.4.3.3. Cancer

            12.4.3.4. Autoimmune Disorders

        12.4.4. Market Value (US$ Mn) Forecast, By End User

            12.4.4.1. Hospitals

            12.4.4.2. Long-term Care Facilities

            12.4.4.3. Research institutes

        12.4.5. Market Attractiveness Analysis

            12.4.5.1. By Country

            12.4.5.2. By Product Type

            12.4.5.3. By End User

            12.4.5.4. By Disease Indication

        12.4.6. Drivers & Restraints: Impact Analysis

13. Eastern Europe Market Analysis

    13.1. Introduction

        13.1.1. Y-o-Y Growth Projections, By Country

        13.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    13.2. Key Regulations

    13.3. Key Trends

    13.4. Eastern Europe Market Forecast

        13.4.1. Market Value (US$ Mn) Forecast, By Country

    13.5. Poland Absolute $ Opportunity

    13.6. Russia Absolute $ Opportunity

    13.7. Rest of Eastern Europe Absolute $ Opportunity

        13.7.1. Market Value (US$ Mn) Forecast, By Product Type

            13.7.1.1. Monoclonal antibodies

            13.7.1.2. Polyclonal antibodies

            13.7.1.3. Antibody-drug complexes (ADCs)

        13.7.2. Market Value (US$ Mn) Forecast, By Disease Indication

            13.7.2.1. Cardiovascular diseases

            13.7.2.2. CNS disorders

            13.7.2.3. Cancer

            13.7.2.4. Autoimmune Disorders

        13.7.3. Market Value (US$ Mn) Forecast, By End User

            13.7.3.1. Hospitals

            13.7.3.2. Long-term Care Facilities

            13.7.3.3. Research institutes

        13.7.4. Market Attractiveness Analysis

            13.7.4.1. By Country

            13.7.4.2. By Product Type

            13.7.4.3. By End User

            13.7.4.4. By Disease Indication

        13.7.5. Drivers & Restraints: Impact Analysis

14. Asia Pacific Excl. Japan Market Analysis

    14.1. Introduction

        14.1.1. Y-o-Y Growth Projections, By Country

        14.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    14.2. Key Regulations

    14.3. Key Trends

    14.4. Asia Pacific Excl. Japan Market Forecast

        14.4.1. Market Value (US$ Mn) Forecast, By Country

            14.4.1.1. China Absolute $ Opportunity

            14.4.1.2. India Absolute $ Opportunity

            14.4.1.3. ASEAN Absolute $ Opportunity

            14.4.1.4. Australia & New Zealand Absolute $ Opportunity

            14.4.1.5. Rest of APEJ Absolute $ Opportunity

        14.4.2. Market Value (US$ Mn) Forecast, By Product Type

            14.4.2.1. Monoclonal antibodies

            14.4.2.2. Polyclonal antibodies

            14.4.2.3. Antibody-drug complexes (ADCs)

        14.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            14.4.3.1. Cardiovascular diseases

            14.4.3.2. CNS disorders

            14.4.3.3. Cancer

            14.4.3.4. Autoimmune Disorders

        14.4.4. Market Value (US$ Mn) Forecast, By End User

            14.4.4.1. Hospitals

            14.4.4.2. Long-term Care Facilities

            14.4.4.3. Research institutes

        14.4.5. Market Attractiveness Analysis

            14.4.5.1. By Country

            14.4.5.2. By Product Type

            14.4.5.3. By End User

            14.4.5.4. By Disease Indication

        14.4.6. Drivers & Restraints: Impact Analysis

15. Japan Market Analysis

    15.1. Introduction

    15.2. Key Regulations

    15.3. Key Trends

    15.4. Japan Market Forecast

        15.4.1. Market Value (US$ Mn) Forecast, By Product Type

            15.4.1.1. Monoclonal antibodies

            15.4.1.2. Polyclonal antibodies

            15.4.1.3. Antibody-drug complexes (ADCs)

        15.4.2. Market Value (US$ Mn) Forecast, By Disease Indication

            15.4.2.1. Cardiovascular diseases

            15.4.2.2. CNS disorders

            15.4.2.3. Cancer

            15.4.2.4. Autoimmune Disorders

        15.4.3. Market Value (US$ Mn) Forecast, By End User

            15.4.3.1. Hospitals

            15.4.3.2. Long-term Care Facilities

            15.4.3.3. Research institutes

        15.4.4. Market Attractiveness Analysis

            15.4.4.1. By Product Type

            15.4.4.2. By End User

            15.4.4.3. By Disease Indication

        15.4.5. Drivers & Restraints: Impact Analysis

16. MEA Market Analysis

    16.1. Introduction

        16.1.1. Y-o-Y Growth Projections, By Country

        16.1.2. Market Share & Basis Point (BPS) Analysis, By Country

    16.2. Key Regulations

    16.3. Key Trends

    16.4. MEA Market Forecast

        16.4.1. Market Value (US$ Mn) Forecast, By Country

            16.4.1.1. GCC Countries Absolute $ Opportunity

            16.4.1.2. South Africa Absolute $ Opportunity

            16.4.1.3. North Africa Absolute $ Opportunity

            16.4.1.4. Rest of MEA Absolute $ Opportunity

        16.4.2. Market Value (US$ Mn) Forecast, By Product Type

            16.4.2.1. Monoclonal antibodies

            16.4.2.2. Polyclonal antibodies

            16.4.2.3. Antibody-drug complexes (ADCs)

        16.4.3. Market Value (US$ Mn) Forecast, By Disease Indication

            16.4.3.1. Cardiovascular diseases

            16.4.3.2. CNS disorders

            16.4.3.3. Cancer

            16.4.3.4. Autoimmune Disorders

        16.4.4. Market Value (US$ Mn) Forecast, By End User

            16.4.4.1. Hospitals

            16.4.4.2. Long-term Care Facilities

            16.4.4.3. Research institutes

        16.4.5. Market Attractiveness Analysis

            16.4.5.1. By Country

            16.4.5.2. By Product Type

            16.4.5.3. By End User

            16.4.5.4. By Disease Indication

        16.4.6. Drivers & Restraints: Impact Analysis

17. Competition Landscape

    17.1. Company Share Analysis

    17.2. Competition Dashboard

    17.3. Company Profiles Inclusions

        17.3.1. Revenue

        17.3.2. Products/Brand Offerings

        17.3.3. Key developments

        17.3.4. SWOT Analysis

    17.4. Company Profiled

        17.4.1. Novartis AG

        17.4.2. Hoffmann-La Roche Ltd.

        17.4.3. Johnson & Johnson Services, Inc.

        17.4.4. Takeda Pharmaceutical Company Limited

        17.4.5. Amgen Inc.

        17.4.6. Biogen Inc.

        17.4.7. Bristol-Myers Squibb Company

        17.4.8. AbbVie Inc.

        17.4.9. Sanofi

        17.4.10. Eli Lilly and Co.

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031

Table 02: Global Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031

Table 03: Global Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031

Table 04: Global Market Value (US$ Mn) Analysis and Forecast By Region, 2021 – 2031

Table 05: North America Market Value (US$ Mn) Forecast By Country, 2021 – 2031

Table 06: North America Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031

Table 07: North America Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031

Table 08: North America Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031

Table 09: Latin America Market Value (US$ Mn) Forecast By Country, 2021 – 2031

Table 10: Latin America Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031

Table 11: Latin America Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031

Table 12: Latin America Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031

Table 13: Western Europe Market Value (US$ Bn) Forecast By Country, 2021 – 2031

Table 14: Western Europe Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031

Table 15: Western Europe Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031

Table 16: Western Europe Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031

Table 17: Eastern Europe Market Value (US$ Mn) Forecast By Country, 2021 – 2031

Table 18: Eastern Europe Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031

Table 19: Eastern Europe Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031

Table 20: Eastern Europe Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031

Table 21: APEJ Market Value (US$ Mn) Forecast By Country, 2021 – 2031

Table 22: APEJ Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031 APEJ Market BPS Analysis, Market

Table 23: APEJ Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031

Table 24: Japan Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031

Table 25: Japan Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031

Table 26: Japan Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031

Table 27: MEA Market Value (US$ Mn) Forecast By Country, 2021 – 2031

Table 28: MEA Market Value (US$ Mn) Analysis and Forecast By Drug Type, 2021 – 2031

Table 29: MEA Market Value (US$ Mn) Analysis and Forecast By End User, 2021 – 2031

Table 30: MEA Market Value (US$ Mn) Analysis and Forecast By Indication, 2021 – 2031

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Antibody Market Split By Drug Type (2021)

Figure 02: Global Antibody Market Split By Disease Indication (2021)

Figure 03: Global Antibody Market Split By End User (2021)

Figure 04: Global Antibody Market Split By By Region (2021)

Figure 05: Global Market BPS Analysis (%) By Drug Type, 2021 & 2031

Figure 06: Global Market Attractiveness Analysis By Drug Type, 2021 – 2031

Figure 07: Global Market Y-o-Y growth (%) By Drug Type, 2021 – 2031

Figure 08: Global Market Absolute $ Opportunity (US$ Bn) By Monoclonal Segment, 2021 – 2031

Figure 09: Global Market Absolute $ Opportunity (US$ Bn) By Polyclonal Segment, 2021 – 2031

Figure 10: Global Market Absolute $ Opportunity (US$ Bn) By Antibody-drug Complexes (ADC) Drug Type Segment, 2021 – 2031

Figure 11: Global Market BPS Analysis (%) By End User, 2021 & 2031

Figure 12: Global Market Attractiveness Analysis By End User, 2021 – 2031

Figure 13: Global Market Y-o-Y growth (%) By End User, 2021 – 2031

Figure 14: Global Market Absolute $ Opportunity (US$ Bn) By Hospitals Segment, 2021 – 2031

Figure 15: Global Market Absolute $ Opportunity (US$ Bn) By Long-term Care Facilities Segment, 2021 – 2031

Figure 16: Global Market Absolute $ Opportunity (US$ Bn) By Research Institutes Drug Type Segment, 2021 – 2031

Figure 17: Global Market BPS Analysis (%) By Indication, 2021 & 2031

Figure 18: Global Market Attractiveness Analysis By Indication, 2021 – 2031

Figure 19: Global Market Y-o-Y growth (%) By Indication, 2021 – 2031

Figure 20: Global Market Absolute $ Opportunity (US$ Bn) By CNS Disorders Segment, 2021 – 2031

Figure 21: Global Market Absolute $ Opportunity (US$ Bn) By Cardiovascular Diseases Segment, 2021 – 2031

Figure 22: Global Market Absolute $ Opportunity (US$ Mn) By Cancer Segment, 2021 – 2031

Figure 23: Global Market Absolute $ Opportunity (US$ Bn) By Autoimmune Disorders Segment, 2021 – 2031

Figure 24: Global Market BPS Analysis (%) By Region, 2021 & 2031

Figure 25: Global Market Attractiveness Analysis By Region, 2021 – 2031

Figure 26: Global Market Y-o-Y growth (%) By Region, 2021 – 2031

Figure 27: North America Market Absolute $ Opportunity (US$ Bn), 2021 – 2031

Figure 28: Latin America Market Absolute $ Opportunity (US$ Bn), 2021 – 2031

Figure 29: Global Market BPS Analysis (%) By Drug Type, 2021 & 2031

Figure 30: Global Market Attractiveness Analysis By Drug Type, 2021 – 2031

Figure 31: Global Market Y-o-Y growth (%) By Drug Type, 2021 – 2031

Figure 32: Global Market Absolute $ Opportunity (US$ Bn) By Monoclonal Segment, 2021 – 2031

Figure 33: Global Market Absolute $ Opportunity (US$ Bn) By Polyclonal Segment, 2021 – 2031

Figure 34: Global Market Absolute $ Opportunity (US$ Bn) By Antibody-drug Complexes (ADC) Drug Type Segment, 2021 – 2031

Figure 35: Global Market BPS Analysis (%) By End User, 2021 & 2031

Figure 36: Global Market Attractiveness Analysis By End User, 2021 – 2031

Figure 37: Global Market Y-o-Y growth (%) By End User, 2021 – 2031

Figure 38: Global Market Absolute $ Opportunity (US$ Bn) By Hospitals Segment, 2021 – 2031

Figure 39: Global Market Absolute $ Opportunity (US$ Bn) By Long-term Care Facilities Segment, 2021 – 2031

Figure 40: Global Market Absolute $ Opportunity (US$ Bn) By Research Institutes Drug Type Segment, 2021 – 2031

Figure 41: Global Market BPS Analysis (%) By Indication, 2021 & 2031

Figure 42: Global Market Attractiveness Analysis By Indication, 2021 – 2031

Figure 43: Global Market Y-o-Y growth (%) By Indication, 2021 – 2031

Figure 44: Global Market Absolute $ Opportunity (US$ Bn) By CNS Disorders Segment, 2021 – 2031

Figure 45: Global Market Absolute $ Opportunity (US$ Bn) By Cardiovascular Diseases Segment, 2021 – 2031

Figure 46: Global Market Absolute $ Opportunity (US$ Mn) By Cancer Segment, 2021 – 2031

Figure 47: Global Market Absolute $ Opportunity (US$ Bn) By Autoimmune Disorders Segment, 2021 – 2031

Figure 48: Global Market BPS Analysis (%) By Region, 2021 & 2031

Figure 49: Global Market Attractiveness Analysis By Region, 2021 – 2031

Figure 50: Global Market Y-o-Y growth (%) By Region, 2021 – 2031

Figure 51: North America Market Absolute $ Opportunity (US$ Bn), 2021 – 2031

Figure 52: Latin America Market Absolute $ Opportunity (US$ Bn), 2021 – 2031

Figure 53: Western Europe Market Absolute $ Opportunity (US$ Bn), 2021 – 2031

Figure 54: Eastern Europe Market Absolute $ Opportunity (US$ Bn), 2021 – 2031

Figure 55: APEJ Market Absolute $ Opportunity (US$ Bn), 2021 – 2031

Figure 56: Japan  Market Absolute $ Opportunity (US$ Bn), 2021 – 2031

Figure 57: MEA Market Absolute $ Opportunity (US$ Bn), 2021 – 2031

Figure 58: North America Market BPS Analysis (%) By Country, 2021 & 2031

Figure 59: North America Market Attractiveness Analysis By Country, 2021 – 2031

Figure 60: North America Market Y-o-Y growth (%) By Country, 2021 – 2031

Figure 61: North America Market BPS Analysis (%) By Drug Type, 2021 & 2031

Figure 62: North America Market Attractiveness Analysis By Drug Type, 2021 – 2031

Figure 63: North America Market Y-o-Y growth (%) By Drug Type, 2021 – 2031

Figure 64: North America Market BPS Analysis (%) By End User, 2021 & 2031

Figure 65: North America Market Attractiveness Analysis By End User, 2021 – 2031

Figure 66: North America Market Y-o-Y growth (%) By End User, 2021 – 2031

Figure 67: North America Market BPS Analysis (%) By Indication, 2021 & 2031

Figure 68: North America Market Attractiveness Analysis By Indication, 2021 – 2031

Figure 69: North America Market Y-o-Y growth (%) By Indication, 2021 – 2031

Figure 70: Latin America Market BPS Analysis (%) By Country, 2021 & 2031

Figure 71: Latin America Market Attractiveness Analysis By Country, 2021 – 2031

Figure 72: Latin America Market Y-o-Y growth (%) By Country, 2021 – 2031

Figure 73: Latin America Market BPS Analysis (%) By Drug Type, 2021 & 2031

Figure 74: Latin America Market Attractiveness Analysis By Drug Type, 2021 – 2031

Figure 75: Latin America Market Y-o-Y growth (%) By Drug Type, 2021 – 2031

Figure 76: Latin America Market BPS Analysis (%) By End User, 2021 & 2031

Figure 77: Latin America Market Attractiveness Analysis By End User, 2021 – 2031

Figure 78: Latin America Market Y-o-Y growth (%) By End User, 2021 – 2031

Figure 79: Latin America Market BPS Analysis (%) By Indication, 2021 & 2031

Figure 80: Latin America Market Attractiveness Analysis By Indication, 2021 – 2031

Figure 81: Latin America Market Y-o-Y growth (%) By Indication, 2021 – 2031

Figure 82: Western Europe Market BPS Analysis (%) By Country, 2021 & 2031

Figure 83: Western Europe Market Attractiveness Analysis By Country, 2021 – 2031

Figure 84: Western Europe Market Y-o-Y growth (%) By Country, 2021 – 2031

Figure 85: Western Europe Market BPS Analysis (%) By Drug Type, 2021 & 2031

Figure 86: Western Europe Market Attractiveness Analysis By Drug Type, 2021 – 2031

Figure 87: Western Europe Market Y-o-Y growth (%) By Drug Type, 2021 – 2031

Figure 88: Western Europe Market BPS Analysis (%) By End User, 2021 & 2031

Figure 89: Western Europe Market Attractiveness Analysis By End User, 2021 – 2031

Figure 90: Western Europe Market Y-o-Y growth (%) By End User, 2021 – 2031

Figure 91: Western Europe Market BPS Analysis (%) By Indication, 2021 & 2031

Figure 92: Western Europe Market Attractiveness Analysis By Indication, 2021 – 2031

Figure 93: Western Europe Market Y-o-Y growth (%) By Indication, 2021 – 2031

Figure 94: Eastern Europe Market BPS Analysis (%) By Country, 2021 & 2031

Figure 95: Eastern Europe Market Attractiveness Analysis By Country, 2021 – 2031

Figure 96: Eastern Europe Market Y-o-Y growth (%) By Country, 2021 – 2031

Figure 97: Eastern Europe Market BPS Analysis (%) By Drug Type, 2021 & 2031

Figure 98: Eastern Europe Market Attractiveness Analysis By Drug Type, 2021 – 2031

Figure 99: Eastern Europe Market Y-o-Y growth (%) By Drug Type, 2021 – 2031

Figure 100: Eastern Europe Market BPS Analysis (%) By End User, 2021 & 2031

Figure 101: Eastern Europe Market Attractiveness Analysis By End User, 2021 – 2031

Figure 102: Eastern Europe Market Y-o-Y growth (%) By End User, 2021 – 2031

Figure 103: Eastern Europe Market BPS Analysis (%) By Indication, 2021 & 2031

Figure 104: Eastern Europe Market Attractiveness Analysis By Indication, 2021 – 2031

Figure 105: Eastern Europe Market Y-o-Y growth (%) By Indication, 2021 – 2031

Figure 106: APEJ Market BPS Analysis (%) By Country, 2021 & 2031

Figure 107: APEJ Market Attractiveness Analysis By Country, 2021 – 2031

Figure 108: APEJ Market Y-o-Y growth (%) By Country, 2021 – 2031

Figure 109: APEJ Market BPS Analysis (%) By End User, 2021 & 2031

Figure 110: APEJ Market Attractiveness Analysis By End User, 2021 – 2031

Figure 111: APEJ Market Y-o-Y growth (%) By End User, 2021 – 2031

Figure 112: APEJ Market BPS Analysis (%) By Indication, 2021 & 2031

Figure 113: APEJ Market Attractiveness Analysis By Indication, 2021 – 2031

Figure 114: APEJ Market Y-o-Y growth (%) By Indication, 2021 – 2031

Figure 115: Japan Market BPS Analysis (%) By Drug Type, 2021 & 2031

Figure 116: Japan Market Attractiveness Analysis By Drug Type, 2021 – 2031

Figure 117Japan Market Y-o-Y growth (%) By Drug Type, 2021 – 2031

Figure 118: Japan Market BPS Analysis (%) By End User, 2021 & 2031

Figure 119: Japan Market Attractiveness Analysis By End User, 2021 – 2031

Figure 120: Japan Market Y-o-Y growth (%) By End User, 2021 – 2031

Figure 121: Japan Market BPS Analysis (%) By Indication, 2021 & 2031

Figure 122: Japan Market Attractiveness Analysis By Indication, 2021 – 2031

Figure 123: Japan Market Y-o-Y growth (%) By Indication, 2021 – 2031

Figure 124: MEA Market BPS Analysis (%) By Country, 2021 & 2031

Figure 125: MEA Market Attractiveness Analysis By Country, 2021 – 2031

Figure 126: MEA Market Y-o-Y growth (%) By Country, 2021 – 2031

Figure 127: MEA Market BPS Analysis (%) By Drug Type, 2021 & 2031

Figure 128: MEA Market Attractiveness Analysis By Drug Type, 2021 – 2031

Figure 129: MEA Market Y-o-Y growth (%) By Drug Type, 2021 – 2031

Figure 130: MEA Market BPS Analysis (%) By End User, 2021 & 2031

Figure 131: MEA Market Attractiveness Analysis By End User, 2021 – 2031

Figure 132: MEA Market Y-o-Y growth (%) By End User, 2021 – 2031

Figure 133: MEA Market BPS Analysis (%) By Indication, 2021 & 2031

Figure 134: MEA Market Attractiveness Analysis By Indication, 2021 – 2031

Figure 135: MEA Market Y-o-Y growth (%) By Indication, 2021 – 2031

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Research Antibodies Market

Published : May 2021

Healthcare

Cardiolipin Antibodies Test Market

Published : October 2019

Healthcare

IVD Antibodies Market

Published : January 2019

Healthcare

Phospho-specific Antibodies Market

Published : December 2018

Google translate